Baraclude: Clinical Trials

18 trials of Baraclude, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 completed, 5 unknown, 3 terminated. 18 Phase 2, 3 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 218Completed 10, Unknown 5, Terminated 3
Phase 13Unknown 2, Completed 1

Follow Baraclude: new trials by email Literature Review of Baraclude trials Research Report on Baraclude

Trials (filtered) newest first · largest first

All 18 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate the Efficacy and Safety of ZM-H1505R in Combination With ETV Compared With ETV Monotherapy in Patients With CHB
ZM-H1505R, ZM-H1505R placebo, Baraclude - Hepatitis B, Chronic
Phase 2UnknownShanghai Zhimeng Biopharma, Inc.902022-11-112023-05-08
A Clinical Study of APG-1387 in Combination With Entecavir in Patients With Chronic Hepatitis B
APG-1387, Entecavir 0.5 mg - Hepatitis B, Chronic Hep B
Phase 2UnknownAscentage Pharma Group Inc.1222020-06-032021-08-26
Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)
ARC-520, entecavir, pegylated interferon alpha 2a - Hepatitis B, Hepatitis D
Phase 2TerminatedArrowhead Pharmaceuticals792015-12-012026-01-13
A Clinical Trial on Hepatitis B Vaccine Activated-Dendritic Cells Combined With Anti-HBV Drugs in CHB
HPDC-T cells & Entecavir, Entecavir, HPDC-T cells & IFN-a-2a - Chronic Hepatitis B
Phase 1 / Phase 2UnknownThird Affiliated Hospital, Sun Yat-Sen University4502015-11-012015-11-26
Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus
ARC-520, Placebo, Entecavir - Chronic Hepatitis B
Phase 2TerminatedArrowhead Pharmaceuticals42015-08-012025-11-03
A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection
ARC-520, Placebo, entecavir - Hepatitis B, Chronic
Phase 2TerminatedArrowhead Pharmaceuticals582014-03-012026-01-13
Entecavir Versus Lamivudine for Preventing the Risk of Hepatitis B Reactivation in NHL
Entecavir, Lamivudine - Non-Hodgkin Lymphoma, Hepatitis B Reactivation
Phase 2UnknownFudan University822013-02-012013-08-02
Pegylated Interferon and Entecavir Combination in Chronic Hepatitis B (CHB)
Pegalyted interferon, Entecavir - Chronic Hepatitis B
Phase 1 / Phase 2UnknownBangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh202012-03-012012-05-02
Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen
pegIFN, pegIFNα-2a, PegIFN lambda - Hepatitis B Virus
Phase 2CompletedBristol-Myers Squibb1972010-11-012015-10-09
Therapeutic Hepatitis B Vaccine (Mimogen-based) Joint Entecavir in Treating Chronic Hepatitis B Patients
Therapeutic HBV vaccine, entecavir, placebo - Chronic Hepatitis B
Phase 2CompletedChongqing Jiachen Biotechnology Ltd.3782010-06-012019-06-26
Safety and Efficacy Study of LB80380 in the Treatment-naive Patients of Chronic Hepatitis B
LB80380 90 mg, LB80380 150 mg, entecavir 0.5 mg - Chronic Hepatitis B
Phase 2CompletedLG Life Sciences1152009-08-012012-10-05
A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection
Entecavir - Hepatitis B, Chronic
Phase 1 / Phase 2CompletedBristol-Myers Squibb642007-06-302018-05-02
Study Comparing Tenofovir Disoproxil Fumarate (TDF), Emtricitabine (FTC)/TDF, and Entecavir (ETV) in the Treatment of Chronic HBV in Subjects With Decompensated Liver Disease.
Tenofovir disoproxil fumarate (tenofovir DF; TDF), Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), Entecavir (ETV) - Chronic Hepatitis B
Phase 2CompletedGilead Sciences1122006-04-012013-04-25
An Open-Label Rollover Study of Entecavir (BMS-200475) in Adults With Chronic Hepatitis B Infection
Entecavir - Chronic Hepatitis B
Phase 2CompletedBristol-Myers Squibb2822003-12-012011-01-31
A Phase II Dose Response Study in Japan in Chronic Hepatitis B
Entecavir - Chronic Hepatitis B
Phase 2CompletedBristol-Myers Squibb1202003-08-012010-02-02
A Study in Japan of the Safety and Antiviral Activity With Chronic Hepatitis B Infection
Entecavir - Chronic Hepatitis B
Phase 2CompletedBristol-Myers Squibb602003-02-012010-08-06
Study in Japan of the Safety And Antiviral Activity in Adults With Chronic Hepatitis B Current Lamivudine Therapy
Entecavir - Chronic Hepatitis B
Phase 2CompletedBristol-Myers Squibb842002-12-012011-01-31
Safety and Antiviral Activity of Entecavir in Participants With Chronic Hepatitis B Following Monotherapy in Other Entecavir Trials
Entecavir, Lamivudine - Hepatitis B Virus, HBV
Phase 2CompletedBristol-Myers Squibb10532001-01-012012-08-23

Conditions studied

Hepatitis B, Chronic (14)  ·  Hepatitis B (6)  ·  Hepatitis (2)  ·  Hepatitis D (1)  ·  Lymphoma, Non-Hodgkin (1)

Sponsors

Bristol-Myers Squibb (7)  ·  Arrowhead Pharmaceuticals (3)  ·  Ascentage Pharma Group Inc. (1)  ·  Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh (1)  ·  Chongqing Jiachen Biotechnology Ltd. (1)  ·  Fudan University (1)  ·  Gilead Sciences (1)  ·  LG Life Sciences (1)  ·  Shanghai Zhimeng Biopharma, Inc. (1)  ·  Third Affiliated Hospital, Sun Yat-Sen University (1)

Countries

China (6)  ·  South Korea (4)  ·  Taiwan (4)  ·  United States (4)  ·  Canada (3)  ·  Australia (2)  ·  France (2)  ·  Germany (2)  ·  Hong Kong (2)  ·  Italy (2)  ·  Japan (2)  ·  Singapore (2)  ·  Argentina (1)  ·  Bangladesh (1)  ·  Belgium (1)

Top investigators

Bruce Given, MD (1)  ·  John Flaherty, PharmD (1)  ·  Junqi Niu (1)  ·  LanJuan Li, Ph.D. (1)  ·  Lubiao Chen, MD.&PHD. (1)  ·  Mamun A Mahtab, MSc MD FACG (1)  ·  Ye Guo, MD (1)  ·  Yifan Zhai, MD, PhD (1)

Results publications

PMID 21254162, PMID 22233350, PMID 26739688, PMID 28611778, PMID 33712437

NIH funding

2015 (1)